Maryam Yousefi Dehbidi

Ms. Maryam Yousefi Dehbidi

Kharazmi University, Tehran, Tehrān, Iran
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2021 in Reviews in Medical Virology
Verified
Journal Article
Open access
PDF file
MDMaryam Yousefi Dehbidi
Maryam Yousefi Dehbidi
NGNima Goodarzi
Nima Goodarzi
MAMohammad H. Azhdari
Mohammad H. Azhdari
Mohammad DoroudianMohammad Doroudian
Mohammad Doroudian
Summary: Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is causing an ongoing pandemic of coronavirus disease 2019 (Covid‐19). Effective therapies are required for the treatment of patients with severe stages of the disease. Mesenchymal stem cells (MSCs) have been evaluated in numerous clinical trials, but present challenges, such as carcinogenic risk and special storage conditions, coupled with insufficient data about their mechanism of action. The majority of unique properties of MSCs are related to their paracrine activity and especially to their exosomes. The impact of MSCs‐derived exosomes (MSC‐Es) on complications of Covid‐19 has been investigated in several studies. MSC‐Es may improve some complications of Covid‐19 such as cytokine storm, acute respiratory distress syndrome (ARDS) and acute lung injury (ALI). Additionally, these exosomes can be evaluated as an applicable nano‐size carrier for antiviral therapeutic agents. Herein, we consider several potential applications of MSCs and their derived exosomes in the treatment of Covid‐19.